Aclaris Therapeutics (ACRS) Net Income towards Common Stockholders (2014 - 2026)

Aclaris Therapeutics' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$37.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 102.61% year-over-year to -$37.5 million; the TTM figure through Mar 2026 stood at -$106.8 million (up 27.77% YoY), while the FY2025 annual figure was -$273.0 million, down 106.7% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$37.5 million, down from -$31.3 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$9.7 million in Q3 2024, with the low at -$197.0 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$32.9 million (2023), against an average of -$42.7 million.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders slumped 349.74% in 2023, then surged 71.08% in 2025.
• Aclaris Therapeutics' Net Income towards Common Stockholders stood at -$43.8 million in 2022, then tumbled by 349.74% to -$197.0 million in 2023, then surged by 45.03% to -$108.3 million in 2024, then jumped by 71.08% to -$31.3 million in 2025, then declined by 19.61% to -$37.5 million in 2026.
• Business Quant data shows ACRS's Net Income towards Common Stockholders at -$37.5 million in Q1 2026, -$31.3 million in Q4 2025, and -$19.2 million in Q3 2025.